ASCO GU 2020: Adding radiotherapy to immunotherapy for the treatment of metastatic kidney cancer

Two clinical trials looking at the use of radiotherapy and immunotherapy for metastatic renal cell carcinoma (RCC) were presented at the American Society of Clinical¬†Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. First was the Phase II NIVES trial. In this trial, advanced kidney cancer patients who had been treated with targeted […]

read more

The case for SBRT as kidney cancer treatment

In this video interview, Dr Vitaly Margulis, from the University of Texas Southwestern Medical Center in Dallas, outlines the advantages of stereotactic body radiation therapy (SBRT) and talks about the forthcoming RADVAX clinical trial in the USA, which combines radiotherapy and immunotherapy. Oncologists are often taught that renal cell carcinoma (RCC) is resistant to radiotherapy. […]

read more

Stereotactic radiation for the treatment of kidney cancer

This paper reviews the use of stereotactic body radiotherapy (SBRT) for the treatment of renal cell carcinoma (RCC), and was presented at the Society of Urologic Oncology (SUO) in Washington last week. In conclusion: RCC is radiosensitive and SBRT can be used to stabilise or manage the symptoms of primary tumours SBRT may be useful […]

read more

SBRT in combination with systemic treatment for metastatic kidney cancer

Two recent studies have looked at the effect of stereotactic body radiotherapy (SBRT) in combination with tyrosine kinase inhibitors or immune checkpoint inhibitors on renal cell carcinoma (RCC) metastases and survival. In the first study, a total of 17 patients with stable metastatic RCC were assessed. The effect of SBRT on the target metastasis was […]

read more

Treatment with stereotactic body radiotherapy plus TKIs or immunotherapy is safe and may improve survival of metastatic kidney cancer patients

Two small studies looked at the addition of a type of radiotherapy treatment, called stereotactic body radiotherapy (SBRT), to treatment with a tyrosine kinase inhibitor (TKI), such as sunitinib or pazopanib, or a checkpoint inhibitor, such as nivolumab for patients with metastatic renal cell carcinoma (RCC). In the first study, 56 patients with metastatic RCC […]

read more

Role of stereotactic ablative radiotherapy for primary renal cell carcinoma

This paper reviews the use of stereotactic ablative radiotherapy (SABR) (also called stereotactic body radiotherapy, SBRT) for treating primary renal cell carcinoma (RCC) that cannot be removed with surgery. SABR is a treatment that automatically targets high doses of radiotherapy to the tumour with high precision. SABR is very accurate, and thereby maximises the cell-killing […]

read more

Stereotactic body radiotherapy may improve control of localised kidney cancer

A recent study published in The Journal of Urology¬†this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC). Fifty-eight RCC patients, who had undergone surgery and had a maximum […]

read more
Showing all 7 results
  TOP